Precision BioSciences Inc. (DTIL): Find Out What Insiders Are Doing


Precision BioSciences Inc. (NASDAQ:DTIL) traded with a subtraction of -$0.1 to $1.26 on Thursday, a downside of -7.36 percent. An average of 1,174,920 shares of common stock have been traded in the last five days. There was a fall of -$0.3813 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 1,032,155 shares traded, while the 50-day average volume stands at 1,488,702.

DTIL stock has decreased by -17.07% in the last month. The company shares reached their 1-month lowest point of $1.2600 on 09/22/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $1.11 and a high of $13.49 in 52 weeks. It has reached a new high 2 times so far this year and lost -81.62% or -$6.1313 in price. In spite of this, the price is down -90.66% from the 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Insider Transactions

106 days have passed since Precision BioSciences Inc. (DTIL) last reported insider trading activity. JANTZ DEREK, who is Chief Scientific Officer, most recently acquired $18,849 shares at $2.06 per share on Jun 08. In this transaction, the insider spent $38,829. General Counsel and Secretary, Scimeca Dario, disposed of 9,833 shares at a price of $2.06 on Jun 08. The insider now owns more than $20,256 worth of shares. Prior to that, Chief Medical Officer List Alan went on to Sale 7,775 shares at $2.10 each on Apr 27. An amount of $16,328 was transacted.

Valuation Metrics

Precision BioSciences Inc. (DTIL) stock’s beta is 1.46. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.36, the price-to-book (PB) ratio at 0.89.

Financial Health

The quick ratio of Precision BioSciences Inc. for the three months ended June 29 was 4.60, and the current ratio was 4.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.21 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $154.93 million compared to revenue of $115.53 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Precision BioSciences Inc.’s return on assets was -40.50%.

Earnings Surprise

For the three-month period that ended June 29, Precision BioSciences Inc. had $22.12 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$31.04 million in the quarter, while revenues of -$28.17 million were grew 169.78%. The analyst consensus anticipated Precision BioSciences Inc.’s latest quarter earnings to come in at -$0.41 per share, but it turned out to be -$0.46, a -12.20% surprise. For the quarter, EBITDA amounted to -$27.46 million. Shareholders own equity worth $110.82 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Precision BioSciences Inc. (DTIL) price momentum. RSI 9-day as of the close on 21 September was 20.69%, suggesting the stock is oversold, with historical volatility in this time frame at 54.71%.

As of today, DTIL’s price is $1.4097 -23.11% or -$0.3813 from its 5-day moving average. DTIL is currently trading -25.37% lower than its 20-day SMA and -36.25% lower than its 100-day SMA. However, the stock’s current price level is -17.08% below the SMA50 and -84.64% below the SMA200.

The stochastic %K and %D were 8.02% and 17.74%, respectively, and the average true range (ATR) was 0.1162. With the 14-day stochastic at 1.81% and the average true range at 0.1217, the RSI (14) stands at 29.95%. The stock has reached -0.1781 on the 9-day MACD Oscillator while the 14-day reading was at -0.2056.

Analyst Ratings

BMO Capital Markets launched coverage on Precision BioSciences Inc. (NASDAQ: DTIL) in its analyst report released on June 17, 2022. The firm assigned the stock an Outperform rating.


Please enter your comment!
Please enter your name here